The prognostic impact of comorbidity, nutritional and performance status on patients with diffuse large B cell lymphoma
Articles > Article · 2020
Authors: B. Saglam, M. Albayrak, A. Yıldız, P. Akyol, M. Tiglioglu, M. Aras, Funda YILMAZ, S. Maral, H. Ozturk
Hematology, Transfusion and Cell Therapy, International, 2020, vol 42, pp 21-21
DOI: 10.1016/j.htct.2020.09.040
Summary
hematol transfus cell ther. 2 0 2 0;4 2(S 1):S17-S34 S21Syndrome (SS) and 3 patients with multifocal primary cutaneous anaplastic large cell lymphoma (pcALCL).The median follow-up was 21.5 (range: 4-60) months from the date of diagnosis.Adverse events were grade 1-2 peripheral neuropathy (40%) and gastro-intestinal disturbances (10%).Peripheral neuropathy resolved by discontinuation of therapy.All there pcALCL patients achieved complete remission after 5 cycle of BV.One patient with MF had progressive disease due to nodal involvement and one died of fungal pneumonia after 2 cycles of BV and could not evaluated for disease response.Conclusion: BV has proven efficacy in both CD30-expressing MF, pcALCL.Same as previous studies, CR could be achieved more frequently in pcALCL than MF in our study.BV is found significantly higher response rates compared to traditional agents like methotrexate or bexarotene and 75% of patients had underwent these therapies before BV.In summary, BV is a promising agent for relapsed refractory CTCL patients with durable remission.